Medicine: Sanofi builds new insulin factory in Frankfurt for billions
The pharmaceutical company is building a new production facility for insulin in Frankfurt. This is important for diabetics and significant far beyond the location. It's about supply issues in Europe.
Sanofi has started building a new insulin production facility in Frankfurt, investing around two billion euros. The facility, set to be operational by 2032, will replace an existing one, ensuring a crisis-resistant insulin supply for diabetics in Germany and Europe, and securing thousands of jobs. The new plant, spanning 36,000 square meters, will utilize artificial intelligence and meet the highest standards.
Sanofi's CEO, Belen Garijo, stated that the facility will be crucial to the company's global insulin supply network, supporting millions of people worldwide who rely on insulin daily. The project received 400 million euros in state aid from the EU Commission in September.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
